entertainment -WSS

entertainment

author：Wikipedia 2025-09-28 00:50:49 - browse：4613

Cell and gene therapy sign seen at a conference. -- biotech coverage from STAT — Jonathan Wosen for STAT

CARLSBAD, Calif. — Biotech CEOs leading cell and gene therapy companies spoke frankly at a conference here last week about the tough choices they’re making to preserve limited cash amid the industry’s ongoing slowdown.

The company leaders said that they’ve felt added pressure to use smaller teams to work quickly on fewer projects, and at times to partner with outside firms that have specific manufacturing and research expertise. Not all of these changes are bad, they added, noting that efficiency is a good trait for a biotech company in any market.

The candid conversation on Thursday was part of Meeting on the Mesa, an annual cell and gene therapy conference held in Carlsbad, in the north of San Diego County. And it provided a glimpse into discussions happening across the life science industry as biotech markets continue a sharp slump that dates back to late 2021.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Kaiser's Risant Health gobbled up Geisinger. Who is next?

WSS

Change Healthcare can notify patients about the breach, HHS says

NIH documents show early flaws of $1.6 billion long Covid program

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

CDC: Uninsured rate hit 'record low' right as states cut Medicaid

Trump drops motion seeking removal of DA probing efforts to overturn 2020 election in Georgia

CDC: Uninsured rate hit 'record low' right as states cut Medicaid

hotspot

entertainment

hotspot

Dobbs anniversary: the lost opportunity of abortion as health care

TytoCare raises $49 million to build out AI

As demand for Covid shots wanes, Moderna seeks its next success

2 US Navy sailors arrested for allegedly spying for China

Alkermes shareholders re

Attacks on the drug industry will lead to fewer breakthroughs

DIEP, the 'gold standard' of breast reconstruction, is under threat

NIH documents show early flaws of $1.6 billion long Covid program

Trump demands the U.S. pay no more for drugs than other countries … again

What the cancer research community can learn from the Covid response

explore

Woman returns to dialysis after doctors remove transplanted pig kidney

OTC birth control: A brief history of over the counter pill design

What the cancer research community can learn from the Covid response

A cyberattack has disrupted hospitals and health care in several states

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

ASCO: AstraZeneca says CAR

knowledge

explore

knowledge

focus